Today: The ProMetic Life Sciences’ (PLI) Outperform Rating Reiterated at Royal Bank Of Canada

The ProMetic Life Sciences’ (PLI) Outperform Rating Reiterated at Royal Bank Of Canada

ProMetic Life Sciences Inc. (TSE:PLI)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Royal Bank Of Canada in a note issued to investors on Thursday, StockTargetPrices.com reports.

PLI has been the topic of several other reports. TD Securities reissued a “speculative buy” rating and issued a C$4.50 target price on shares of ProMetic Life Sciences in a research report on Wednesday, September 28th. Scotiabank reissued an “outperform” rating and issued a C$5.00 target price on shares of ProMetic Life Sciences in a research report on Thursday, August 25th. Finally, CIBC dropped their target price on shares of ProMetic Life Sciences from C$5.00 to C$4.85 in a research report on Thursday, August 25th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of C$4.84.

Shares of ProMetic Life Sciences (TSE:PLI) traded down 1.89% during trading on Thursday, hitting $3.11. 520,719 shares of the stock were exchanged. The stock’s 50 day moving average is $2.92 and its 200-day moving average is $3.01. The stock’s market cap is $1.88 billion. ProMetic Life Sciences has a 12-month low of $1.67 and a 12-month high of $3.62.

ProMetic Life Sciences Company Profile

Related posts

Leave a Comment